| Name | Cabergoline |
| Description | Cabergoline (FCE-21336) is an ergot derived-dopamine D2-like receptor agonist. It has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively).Cabergoline permits rapid and effective hormonal and tumor control by normalizing prolactin-producing pituitary adenomas levels. |
| In vitro | Cabergoline(10 μM) is used to investigate its neuroprotective effects. MAP2 staining reveals that Cabergoline significantly suppresses the loss of neurons caused by H2O2 incubation. Pretreatment with Cabergoline inhibits H2O2-induced neuronal cell death in a dose-dependent manner. Cabergoline prevents apoptotic cell death following H2O2 exposure [1]. |
| In vivo | Cabergoline demonstrates a longer elimination half-life (63 to 109 hours) compared to other D2-like receptor agonists, offering prolonged clinical benefits from a single dose and potential enhancements in the quality of life for individuals with chronic conditions [1]. It notably reduces the number of rapid eye movement (REM) sleep bouts in female mice, achieving a 67.3% reduction (F(1,11)=12.892, P=0.004) in non-restrained subjects, with the most considerable decrease observed during the dark phase (82.3% reduction). In male mice, Cabergoline significantly lowers baseline Prolactin (PRL) levels by 98.5% (F(1,6)=13.192, P=0.011) to 0.08 ng/mL within two hours post-injection. PRL levels normalize to baseline (5.0±0.60 ng/mL; F(1,6)=0.715, P=0.43) following a seven-day recovery period [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 260 mg/mL (575.73 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.43 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | FCE21336 | FCE 21336 | DopamineReceptor | Dopamine Receptor | Dopamine D3 receptor | Dopamine D2 receptor | Dopamine | D3 | D2 | Cabergoline | Autophagy | 5HTReceptor | 5-HT2B receptor | 5-HT2B | 5HT Receptor |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Guanidine hydrochloride | Hydroxychloroquine | Enzalutamide | Paeonol | Naringin | Alginic acid |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Pain-Related Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Active Compound Library |
United States
